Aurobindo faces US suit over carcinogenic elements in blood pressure drug

Aurobindo scrip lost as much as Rs 22 (down close to 3%) on Tuesday after touching a new 52-week high of Rs 830

Hyderabad-based drug major Aurobindo Pharma has been named in a class action lawsuit in the US for alleged contamination of its irbesartan active ingredient (API) used in treatment of high blood pressure.

The lawsuit was filed in the Federal Court of Florida against Aurobido Pharma and also US-based pharmaceutical company Sciegen Pharmaceuticals, which used Aurobindo’s irbesartan API to make its own blood pressure lowering product. Distributor Westminster Pharmaceuticals and the US retail supply chain Walmart were also named in the lawsuit.  

Aurobindo scrip lost as much as Rs 22 (down close to 3 per cent) on Tuesday after touching a